Moreover, recent studies have identified CCL2 and CCL3 as significant biomarkers for inflammatory IIIA and non-inflammatory IIIB chronic pelvic pain symptoms, underscoring their potential clinical significance in the diagnosis and management of prostatitis (146). This evidence concerns the gene CCL2 and urogenital neoplasm.